Superstring Capital Management’s UroGen Pharma URGN Stock Holding History

Superstring Capital Management’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.96M	Sell	387,371 -330,983	-46%	-$6.64M	4.98%	5
2025 Q4	$16.8M	Buy	718,354 +630,442	+717%	+$13.7M	9.01%	3
2025 Q3	$1.75M	Hold	87,912	–	–	1.73%	23
2025 Q2	$1.2M	Sell	87,912 -335,720	-79%	-$3.22M	1.43%	23
2025 Q1	$4.69M	Buy	423,632 +122,426	+41%	+$1.31M	5.57%	6
2024 Q4	$3.21M	Buy	+301,206	New	+$3.61M	2.78%	10
2024 Q2	–	Sell	-288,267	Closed	-$4.32M	–	56
2024 Q1	$4.32M	Buy	288,267 +32,837	+13%	+$537K	2.86%	13
2023 Q4	$3.83M	Buy	+255,430	New	+$3.32M	2.73%	12

Other funds holding URGN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Superstring Capital Management's URGN Position: Q1 2026 in Review

Superstring Capital Management reduced its UroGen Pharma (URGN) stake by 46% in Q1 2026, selling an estimated $6.64M and leaving 387,371 shares worth $6.96M. The position accounts for 4.98% of the portfolio, ranked #5.

Superstring Capital Management first reported a position in URGN in Q4 2023 and has held it in 8 quarters since. The position peaked at $16.8M in Q4 2025. 172 funds tracked by Wall St. Rank hold URGN as of Q1 2026.

Superstring Capital Management held 387,371 shares of UroGen Pharma worth $6.96M as of Q1 2026.
Superstring Capital Management sold 330,983 UroGen Pharma shares in Q1 2026, an estimated $6.64M.
UroGen Pharma made up 4.98% of Superstring Capital Management's portfolio in Q1 2026, its #5 holding.
Superstring Capital Management first reported a position in UroGen Pharma in Q4 2023 and has held it in 8 quarters since.
Superstring Capital Management's UroGen Pharma position peaked at $16.8M in Q4 2025.
172 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2026.

Based on Superstring Capital Management's 13F filing for Q1 2026, filed 14 May 2026.